Cargando…

Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders

Objective: To evaluate the long-term (18 months) effectiveness, safety, and factors that may predict the success of low-intensity shockwave lithotripsy (Li-SWT) in patients with erectile dysfunction (ED) who fail to respond to oral phosphodiesterase type 5 inhibitors (PDE5i). Patients and Methods: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Musa, Zubairu S., El-Assmy, Ahmed, Shokry, Ahmad M., Shokeir, Ahmed A., Zween, Tamer, Al-Kenawy, Mahmoud R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006645/
https://www.ncbi.nlm.nih.gov/pubmed/32082635
http://dx.doi.org/10.1080/2090598X.2019.1688072
_version_ 1783495190922657792
author Musa, Zubairu S.
El-Assmy, Ahmed
Shokry, Ahmad M.
Shokeir, Ahmed A.
Zween, Tamer
Al-Kenawy, Mahmoud R.
author_facet Musa, Zubairu S.
El-Assmy, Ahmed
Shokry, Ahmad M.
Shokeir, Ahmed A.
Zween, Tamer
Al-Kenawy, Mahmoud R.
author_sort Musa, Zubairu S.
collection PubMed
description Objective: To evaluate the long-term (18 months) effectiveness, safety, and factors that may predict the success of low-intensity shockwave lithotripsy (Li-SWT) in patients with erectile dysfunction (ED) who fail to respond to oral phosphodiesterase type 5 inhibitors (PDE5i). Patients and Methods: This prospective study included 52 patients with ED of vascular origin who failed to respond to oral PDE5i. The International Index of Erectile Function-Erectile Function domain (IIEF-EF) and Erection Hardness Score (EHS) questionnaires were used to evaluate EF. Patients under went two Li-SWT treatment sessions per week for 3 weeks, followed by a 3-week treatment-free period, and the cycle was repeated until each patient received 12 treatment sessions. Patients were followed-up after Li-SWT at 3, 6, 12, and 18 months. Results: At the 18-month follow-up, 33 patients (63.5%) were able to achieve an erection sufficient for penetration with or without PDE5i (22 were maintained on oral PDE5i). The remaining 19 patients (36.5%) had a poor response to Li-SWT and oral PDE5i. The initial response showed some decline in 50% of the initial responders. Younger men (aged <45 years), short ED duration (<2 years), and moderate ED severity responded better to Li-SWT. There were no adverse side-effects. Conclusion: In the present study, Li-SWT was a safe and effective treatment in 63.5% of men with ED who failed to respond to oral PDE5i. Factors such as age (<45 years), ED duration (<2 years), and ED severity can predict treatment outcome in such patients. Abbreviations: CDU: colour Doppler ultrasonography; ED: erectile dysfunction; EDV: end-diastolic velocity; EF: erectile function; EHS: Erection Hardness Score; FU: follow-up; IIEF-EF: International Index of Erectile Function-EF domain; Li-SWT: low-intensity shockwave lithotripsy; PDE5i: phosphodiesterase type 5 inhibitors; PGE1: prostaglandin E1; PSV: peak systolic velocity; RI: resistive index; VOD: veno-occlusive dysfunction
format Online
Article
Text
id pubmed-7006645
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-70066452020-02-20 Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders Musa, Zubairu S. El-Assmy, Ahmed Shokry, Ahmad M. Shokeir, Ahmed A. Zween, Tamer Al-Kenawy, Mahmoud R. Arab J Urol Andrology/Sexual Dysfunction Objective: To evaluate the long-term (18 months) effectiveness, safety, and factors that may predict the success of low-intensity shockwave lithotripsy (Li-SWT) in patients with erectile dysfunction (ED) who fail to respond to oral phosphodiesterase type 5 inhibitors (PDE5i). Patients and Methods: This prospective study included 52 patients with ED of vascular origin who failed to respond to oral PDE5i. The International Index of Erectile Function-Erectile Function domain (IIEF-EF) and Erection Hardness Score (EHS) questionnaires were used to evaluate EF. Patients under went two Li-SWT treatment sessions per week for 3 weeks, followed by a 3-week treatment-free period, and the cycle was repeated until each patient received 12 treatment sessions. Patients were followed-up after Li-SWT at 3, 6, 12, and 18 months. Results: At the 18-month follow-up, 33 patients (63.5%) were able to achieve an erection sufficient for penetration with or without PDE5i (22 were maintained on oral PDE5i). The remaining 19 patients (36.5%) had a poor response to Li-SWT and oral PDE5i. The initial response showed some decline in 50% of the initial responders. Younger men (aged <45 years), short ED duration (<2 years), and moderate ED severity responded better to Li-SWT. There were no adverse side-effects. Conclusion: In the present study, Li-SWT was a safe and effective treatment in 63.5% of men with ED who failed to respond to oral PDE5i. Factors such as age (<45 years), ED duration (<2 years), and ED severity can predict treatment outcome in such patients. Abbreviations: CDU: colour Doppler ultrasonography; ED: erectile dysfunction; EDV: end-diastolic velocity; EF: erectile function; EHS: Erection Hardness Score; FU: follow-up; IIEF-EF: International Index of Erectile Function-EF domain; Li-SWT: low-intensity shockwave lithotripsy; PDE5i: phosphodiesterase type 5 inhibitors; PGE1: prostaglandin E1; PSV: peak systolic velocity; RI: resistive index; VOD: veno-occlusive dysfunction Taylor & Francis 2019-11-11 /pmc/articles/PMC7006645/ /pubmed/32082635 http://dx.doi.org/10.1080/2090598X.2019.1688072 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Andrology/Sexual Dysfunction
Musa, Zubairu S.
El-Assmy, Ahmed
Shokry, Ahmad M.
Shokeir, Ahmed A.
Zween, Tamer
Al-Kenawy, Mahmoud R.
Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders
title Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders
title_full Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders
title_fullStr Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders
title_full_unstemmed Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders
title_short Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders
title_sort long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders
topic Andrology/Sexual Dysfunction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006645/
https://www.ncbi.nlm.nih.gov/pubmed/32082635
http://dx.doi.org/10.1080/2090598X.2019.1688072
work_keys_str_mv AT musazubairus longtermeffectivenessandpredictorsofsuccessoflowintensityshockwavetherapyinphosphodiesterasetype5inhibitorsnonresponders
AT elassmyahmed longtermeffectivenessandpredictorsofsuccessoflowintensityshockwavetherapyinphosphodiesterasetype5inhibitorsnonresponders
AT shokryahmadm longtermeffectivenessandpredictorsofsuccessoflowintensityshockwavetherapyinphosphodiesterasetype5inhibitorsnonresponders
AT shokeirahmeda longtermeffectivenessandpredictorsofsuccessoflowintensityshockwavetherapyinphosphodiesterasetype5inhibitorsnonresponders
AT zweentamer longtermeffectivenessandpredictorsofsuccessoflowintensityshockwavetherapyinphosphodiesterasetype5inhibitorsnonresponders
AT alkenawymahmoudr longtermeffectivenessandpredictorsofsuccessoflowintensityshockwavetherapyinphosphodiesterasetype5inhibitorsnonresponders